PSMA I&T combines a high-affinity peptide motif with a chelator system tuned for imaging-ligand research. Residue placement supports receptor engagement and structural stability. Researchers examine its metal-binding behavior and solution conformation. Applications include receptor-mapping studies, ligand optimization, and chelator-peptide integration.
CAT No: R2559
CAS No:2192281-54-0
Synonyms/Alias:PSMA I&T;2192281-54-0;PSMA-I&T?;SCHEMBL22011359;EX-A5972;DA-57198;MS-32188;HY-148761;CS-0638882;(2S)-2-[[(1S)-1-carboxy-5-[[8-[[(5R)-5-carboxy-5-[[(2R)-2-[[(2R)-2-[[4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]butanoyl]amino]-3-(4-hydroxy-3-iodophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]pentyl]amino]-8-oxooctanoyl]amino]pentyl]carbamoylamino]pentanedioic acid;
Psma I&T, or Prostate-Specific Membrane Antigen Inhibitor and Therapy, is a synthetic peptide-based compound designed for high-affinity binding to the prostate-specific membrane antigen (PSMA). As a member of the growing class of PSMA-targeting ligands, it has garnered significant attention in biochemical and molecular imaging research due to its robust selectivity and versatility in conjugation. The molecular architecture of Psma I&T enables it to serve as a valuable tool for the development of targeted probes, radiolabeled agents, and molecular diagnostics, making it a cornerstone in the study of PSMA-expressing biological systems. Its peptide backbone allows for precise modifications, facilitating a wide range of experimental approaches in both in vitro and in vivo research settings.
Targeted molecular imaging: One of the principal applications of Psma I&T lies in the development of targeted imaging agents for preclinical studies. By conjugating the peptide with various radioisotopes or fluorescent labels, researchers can generate highly specific probes for visualizing PSMA expression in cell-based assays and animal models. This targeted imaging approach enables detailed mapping of PSMA-positive tissues, supporting investigations in oncology, tissue distribution, and receptor localization. The specificity conferred by the peptide scaffold minimizes background signal, thereby improving the resolution and interpretability of imaging data in experimental workflows.
Radioligand development: The compound serves as a foundational scaffold for the synthesis of radiolabeled ligands used in the exploration of PSMA biology. By incorporating suitable chelators or prosthetic groups, Psma I&T can be readily adapted for labeling with a variety of radionuclides, such as gallium-68 or lutetium-177, for use in positron emission tomography (PET) or single-photon emission computed tomography (SPECT) studies. These radioligands enable quantitative analysis of PSMA expression, receptor occupancy, and pharmacokinetics in preclinical models, advancing the understanding of PSMA-mediated pathways and supporting the validation of new molecular targets.
Peptide-based drug delivery research: The high affinity and selectivity of Psma I&T for PSMA make it an attractive vector for targeted delivery applications. Researchers can exploit its binding properties to direct therapeutic payloads, nanoparticles, or other functional moieties to PSMA-expressing cells in vitro or in animal models. Such targeted delivery systems are instrumental in evaluating the efficiency of receptor-mediated uptake, intracellular trafficking, and payload release, thereby informing the design of next-generation delivery platforms for experimental therapeutics and diagnostics.
Receptor binding and affinity studies: Psma I&T is extensively employed in biochemical assays to characterize PSMA-ligand interactions. Through techniques such as surface plasmon resonance, radioligand binding assays, or fluorescence polarization, the peptide enables detailed quantification of binding kinetics, affinity constants, and receptor density. These studies provide critical insights into the molecular determinants of ligand recognition, inform structure-activity relationship (SAR) analyses, and support the rational optimization of PSMA-targeting agents for research use.
Biosensor and assay development: The robust and selective binding properties of Psma I&T underpin its utility in the creation of sensitive biosensors and analytical assays for PSMA detection. By immobilizing the peptide on sensor surfaces or integrating it into assay platforms, researchers can construct highly specific detection systems for quantifying PSMA in biological samples. Such biosensors and assays facilitate high-throughput screening, biomarker validation, and molecular profiling in preclinical research, expanding the toolkit for PSMA-related biochemical investigations.
1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
2. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. Myotropic activity of allatostatins in tenebrionid beetles
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More